Sichenzia Ross Ference Carmel LLP Represents EF Hutton LLC in a $2 Million Common Stock Offering of NRx Pharmaceuticals, Inc.

New York, NY – April 22, 2024 – Sichenzia Ross Ference Carmel LLP (SRFC) announced that it represented EF Hutton LLC as the sole book-runner in a public offering of NRx Pharmaceuticals, Inc. (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company. The pricing of its underwritten public offering of shares of its common stock are at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses.

The SRFC team was led by partners Ross Carmel, Avital Perlman and associate Christian Lichtenberger.